Skip to content
ES
MARKETS / NASDAQ / ORGO
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Organogenesis Holdings Inc. ORGO

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$564.2M
▲ 17.0% YoY
$37.0M
▲ 4201.0% YoY
$-24.5M
▼ 685.7% YoY
In brief

What this company does

Organogenesis develops, manufactures, and sells products for the advanced wound care and surgical and sports medicine markets. It offers its products and in-house customer support to health care customers including hospitals, wound care centers, government facilities, ambulatory surgery centers and physician offices. As of December 31, 2025, it had approximately 854 employees worldwide. As of December 31, 2025, it had 224 direct sales representatives and approximately 175 independent agencies. Its Apligraf product is distributed by its direct sales force in Switzerland, and through independent sales agents in Saudi Arabia and Kuwait. It conducts research and development activities at laboratory facilities in Canton, MA, Birmingham, AL, and San Diego, CA. As of December 31, 2025, it owned 53 issued patents globally, of which 21 were United States patents.

Written from the business description in ORGANOGENESIS HOLDINGS INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 564.2M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 564.2 · Net income 37.0
200.0M400.0M-25.0M-50.0M2016201720182019202020212022202320242025
Compound annual growth
+7.8%
+10.8%
+33.6%
+16.5%
+7.7%
+0.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +10.8% a year over five years — but profit grew faster: net income at +16.5%, earnings per share at +0.0%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
7 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 7.9% · Net 6.6%
10%20%-10%-20%-30%2016201720182019202020212022202320242025
ROE
FY2025 · ROE 13.2%
-200%-400%2016201720182019202020212022202320242025
Gross margin—
Operating margin7.9%
Net margin6.6%
Return on assets6.8%
EBITDAUSD 60.0M

Each USD of equity produced 13 cents of profit this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -24.5
20.0M-25.0M-50.0M2016201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2024 · Dividends — · Net buybacks 24.2
10M20M202220232024
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 598.7M
EquityUSD 300.1M
CashUSD 93.7M
Current ratio3.62×

Equity funds 50% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.60.50.40.50.50.30.30.20.20.1
Operating income $B0.0−0.00.00.00.10.0−0.0−0.1−0.0−0.0
EBITDA $B0.10.00.00.00.10.0−0.0−0.0−0.0−0.0
Income tax $B0.0−0.00.00.0−0.00.00.00.0−0.00.0
Net income $B0.00.00.00.00.10.0−0.0−0.1−0.0−0.0
Free cash flow $B−0.00.00.0−0.00.0−0.0−0.0−0.1−0.0−0.0
EPS, diluted $0.150.010.040.120.700.15−0.42−0.94−0.14−0.27
Dividend / sh $··········
Payout %··········
ROE %13.20.31.86.149.217.8−84.2−526.6··
Shares out B0.130.130.130.130.130.000.100.090.07·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 46 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2016

Share this section

Download image